Brokerages expect Bristol-Myers Squibb Co (NYSE:BMY) to post $5.29 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Bristol-Myers Squibb’s earnings, with estimates ranging from $5.20 billion to $5.43 billion. Bristol-Myers Squibb posted sales of $5.24 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 1%. The firm is expected to announce its next quarterly earnings results before the market opens on Monday, February 5th.
On average, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.29 billion for the current year, with estimates ranging from $20.44 billion to $20.76 billion. For the next fiscal year, analysts forecast that the firm will report sales of $21.13 billion per share, with estimates ranging from $20.82 billion to $21.51 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the firm earned $0.77 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis.
Bristol-Myers Squibb (NYSE:BMY) traded up $1.11 during trading on Monday, reaching $63.39. 803,603 shares of the company traded hands, compared to its average volume of 7,222,631. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $66.10. The stock has a market cap of $103,140.00, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.52%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is presently 62.99%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the stock. Blue Chip Partners Inc. grew its position in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the period. Chilton Investment Co. LLC boosted its stake in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the period. Keel Point LLC boosted its stake in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 39 shares during the period. Finally, Hudock Capital Group LLC boosted its stake in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 49 shares during the period. 69.75% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/22/zacks-analysts-anticipate-bristol-myers-squibb-co-bmy-will-announce-quarterly-sales-of-5-29-billion.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.